Challenges and achievements of liquid biopsy technologies employed in early breast cancer
Alfonso Alba-Bernal, Rocío Lavado-Valenzuela, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, María Isabel Queipo‐Ortuño, Emilio Alba, Iñaki Comino‐Méndez
Abstract
Breast cancer is the most common cancer type in women worldwide and its early detection is crucial to curing the disease. Tissue biopsy, currently the method of choice to obtain tumour molecular information, is invasive and might be affected by tumour heterogeneity rendering it incapable to portray the complete molecular picture. Liquid biopsy permits to study disease features in a more comprehensive manner by sampling biofluids and extracting tumour components such as circulating-tumour DNA (ctDNA), circulating-tumour cells (CTCs), and/or circulating-tumour RNA (ctRNA) amongst others in a monitoring-compatible manner. In this review, we describe the recent progress in the utilization of the circulating tumour components using early breast cancer samples. We review the most important analytes and technologies employed for their study.